Day after Gilead details unexpectedly big rebates

Obamacare Panel Announces Funding To Compare Hep C Rx, Diagnostics

By John Wilkerson / February 5, 2015 at 8:32 PM
A day after Gilead Sciences executives projected larger than expected discounts on hepatitis C medications, Obamacare's comparative-effectiveness research panel on Wednesday (Feb. 4) offered $50 million to compare diagnostics and drugs for hepatitis C, according to a release from the Patient-Centered Outcomes Research Institute. The hepatitis C funding is part of $138 million worth of research grants. The other $88 million funds a range of projects, $12 million of which is for rare diseases research. Hepatitis C drugs sparked a...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.